skip to content
Pharmacoeconomic review report. Sarilumab (Kevzara). Preview this item
ClosePreview this item
Checking...

Pharmacoeconomic review report. Sarilumab (Kevzara).

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : CADTH, May 2017.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : National government publication : English
Summary:
Sarilumab (Kevzara) for subcutaneous (SC) injection is a fully human immunoglobulin G1 monoclonal antibody that binds specifically to both soluble and membrane-bound interleukin-6 receptors inhibiting interleukin-6 mediated signalling. It is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Tables
Material Type: Document, Government publication, National government publication, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1084801120
Description: 1 online resource (1 PDF file (vii, 9 pages)).
Series Title: Common drug review clinical review report.
Other Titles: Sarilumab (Kevzara)

Abstract:

Sarilumab (Kevzara) for subcutaneous (SC) injection is a fully human immunoglobulin G1 monoclonal antibody that binds specifically to both soluble and membrane-bound interleukin-6 receptors inhibiting interleukin-6 mediated signalling. It is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs). Sarilumab is available in 150 mg and 200 mg single-use pre-filled syringes for SC injection. The recommended dose of sarilumab is 200 mg SC injection every two weeks, with a reduction to 150 mg every two weeks for management of neutropenia, thrombocytopenia, and elevated liver enzymes. Sarilumab should be given in combination with methotrexate or other conventional DMARD but may be used as monotherapy in cases of intolerance or contraindication to methotrexate or DMARDs. The manufacturer has submitted a price of $700 per pre-filled syringe (for both 150 mg and 200 mg doses) resulting in an annual cost of $18,200 per patient.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1084801120> # Pharmacoeconomic review report. Sarilumab (Kevzara).
    a schema:MediaObject, schema:CreativeWork, schema:Book ;
    library:oclcnum "1084801120" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8902946468#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
    schema:about <http://experiment.worldcat.org/entity/work/data/8902946468#Topic/antirheumatic_agents> ; # Antirheumatic Agents
    schema:about <http://experiment.worldcat.org/entity/work/data/8902946468#Topic/antibodies_monoclonal_humanized_therapeutic_use> ; # Antibodies, Monoclonal, Humanized--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8902946468#Topic/antibodies_monoclonal_humanized_economics> ; # Antibodies, Monoclonal, Humanized--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8902946468#Topic/arthritis_rheumatoid_drug_therapy> ; # Arthritis, Rheumatoid--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/8902946468#Place/canada> ; # Canada.
    schema:alternateName "Sarilumab (Kevzara)" ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8902946468#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2017" ;
    schema:description "Sarilumab (Kevzara) for subcutaneous (SC) injection is a fully human immunoglobulin G1 monoclonal antibody that binds specifically to both soluble and membrane-bound interleukin-6 receptors inhibiting interleukin-6 mediated signalling. It is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs). Sarilumab is available in 150 mg and 200 mg single-use pre-filled syringes for SC injection. The recommended dose of sarilumab is 200 mg SC injection every two weeks, with a reduction to 150 mg every two weeks for management of neutropenia, thrombocytopenia, and elevated liver enzymes. Sarilumab should be given in combination with methotrexate or other conventional DMARD but may be used as monotherapy in cases of intolerance or contraindication to methotrexate or DMARDs. The manufacturer has submitted a price of $700 per pre-filled syringe (for both 150 mg and 200 mg doses) resulting in an annual cost of $18,200 per patient."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8902946468> ;
    schema:genre "Government publication"@en ;
    schema:genre "National government publication"@en ;
    schema:genre "Tables"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8902946468#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8902946468#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:name "Pharmacoeconomic review report. Sarilumab (Kevzara)."@en ;
    schema:productID "1084801120" ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK534401/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1084801120> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8902946468#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8902946468#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1084801120> ; # Pharmacoeconomic review report. Sarilumab (Kevzara).
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8902946468#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1084801120> ; # Pharmacoeconomic review report. Sarilumab (Kevzara).
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8902946468#Topic/antibodies_monoclonal_humanized_economics> # Antibodies, Monoclonal, Humanized--economics
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal, Humanized--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8902946468#Topic/antibodies_monoclonal_humanized_therapeutic_use> # Antibodies, Monoclonal, Humanized--therapeutic use
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal, Humanized--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8902946468#Topic/antirheumatic_agents> # Antirheumatic Agents
    a schema:Intangible ;
    schema:name "Antirheumatic Agents"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8902946468#Topic/arthritis_rheumatoid_drug_therapy> # Arthritis, Rheumatoid--drug therapy
    a schema:Intangible ;
    schema:name "Arthritis, Rheumatoid--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8902946468#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
    schema:name "Cost-Benefit Analysis"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.